■血清特异性抗体作为有效诊断特发性膜性肾病和评估临床病理的非侵入性手段。
■抗PLA2R和THSD7A抗体与肾组织PLA2R的免疫荧光,检测IMN和非IMN(2020-2021)中的THSD7A和IgG4表达以评估诊断IMN的功效。IMN患者分为两组,抗PLA2R抗体阳性(161例)和阴性(26例),和两组,肾组织PLA2R(40例)和PLA2R+THSD7A(6例),为了比较临床和病理特征,并对THSD7A阳性患者进行预后分析,重点关注与恶性肿瘤的相关性。
■IMN中抗PLA2R抗体的阳性率明显高于IMN(P<0.05);抗PLA2R抗体,肾组织PLA2R、IgG4和THSD7A具有一定的诊断价值。抗PLA2R抗体与IMN患者蛋白尿水平相关,且其水平与血白蛋白呈负相关(r=-0.146,P=0.042);与病理分期及C3、IgG4免疫沉积相关;肾组织THSD7A+PLA2R阳性患者的临床病理与肾组织PLA2R阳性患者比较差异无统计学意义,但是完全缓解的可能性很低,时间更长,随访期间未发现恶性肿瘤事件.
■抗PLA2R抗体,肾组织PLA2R,THSD7A和IgG4对IMN具有较高的诊断效能;抗PLA2R抗体可作为诊断标志物,辅助评估临床和病理特征;肾组织PLA2R和THSD7A的共表达在评估临床特征方面与肾组织PLA2R无显著差异。病理表现和预后,但需要长期的。然而,需要长期随访以监测潜在风险,预计将进行一项具有长期随访的大型多中心研究,以全面评估IMN特征。
UNASSIGNED: Serum-specific antibodies as a non-invasive means to effectively diagnose idiopathic membranous nephropathy and assess clinicopathology.
UNASSIGNED: Immunofluorescence of anti-
PLA2R and THSD7A antibodies and kidney tissue
PLA2R, THSD7A and IgG4 expression in IMN and non-IMN (2020-2021) was detected to assess the efficacy of diagnosing IMN. IMN patients were divided into two groups, anti-
PLA2R antibody positive (161 cases) and negative (26 cases), and two groups, kidney tissue
PLA2R (40 cases) and
PLA2R+THSD7A (6 cases), to compare the clinical and pathological features, and to carry out a prognostic analysis of THSD7A-positive patients, with a focus on correlation with malignancy.
UNASSIGNED: The positive rate of anti-PLA2R antibodies was significantly higher in IMN (P<0.05); anti-
PLA2R antibodies, kidney tissue
PLA2R and IgG4 and THSD7A had some diagnostic value. Anti-PLA2R antibodies correlated with proteinuria levels in IMN patients, and their levels were negatively correlated with blood albumin (r=-0.146, P=0.042); correlated with pathological stage and C3 and IgG4 immunodeposition; there was no significant difference in clinical pathology between kidney tissue THSD7A+PLA2R positive compared to kidney tissue PLA2R positive patients, but the probability of achieving complete remission was low and time longer, and no malignancy events were detected during follow-up.
UNASSIGNED: Anti-
PLA2R antibodies, kidney tissue
PLA2R, THSD7A and IgG4 have high diagnostic efficacy for IMN; anti-PLA2R antibodies can be used as diagnostic markers to assist in the assessment of clinical and pathological features; co-expression of kidney tissue PLA2R and THSD7A is not significantly different from kidney tissue PLA2R in assessing the clinical features, pathological manifestations and prognosis, but requires long-term. However, long-term follow-up is needed to monitor the potential risk, and a larger multicentre study with long-term follow-up is expected to be conducted to comprehensively assess IMN characteristics.